$2.34
1.68% yesterday
Nasdaq, Nov 07, 10:02 pm CET
ISIN
US12529R1077
Symbol
CCCC

C4 Therapeutics Inc Stock price

$2.34
+0.08 3.54% 1M
+0.84 56.00% 6M
-1.26 35.00% YTD
-3.70 61.26% 1Y
-6.52 73.59% 3Y
-24.27 91.21% 5Y
-16.66 87.68% 10Y
-16.66 87.68% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.04 1.68%
ISIN
US12529R1077
Symbol
CCCC
Industry

Key metrics

Basic
Market capitalization
$217.8m
Enterprise Value
$3.2m
Net debt
positive
Cash
$214.6m
Shares outstanding
71.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.4 | 7.6
EV/Sales
0.1 | 0.1
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
61.8%
Return on Equity
-48.8%
ROCE
-49.0%
ROIC
-222.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$34.2m | $28.6m
EBITDA
$-121.6m | $-113.2m
EBIT
$-123.6m | $-121.3m
Net Income
$-111.6m | $-112.6m
Free Cash Flow
$-87.6m
Growth (TTM | estimate)
Revenue
16.5% | -19.5%
EBITDA
-6.1% | 1.9%
EBIT
-6.1% | -3.5%
Net Income
-3.4% | -6.9%
Free Cash Flow
-11.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-355.2% | -395.3%
EBIT
-361.0%
Net
-325.9% | -393.0%
Free Cash Flow
-255.8%
More
EPS
$-1.6
FCF per Share
$-1.2
Short interest
6.1%
Employees
110
Rev per Employee
$320.0k
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a C4 Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34 34
17% 17%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
1% 1%
118%
- Research and Development Expense 118 118
12% 12%
344%
-122 -122
6% 6%
-355%
- Depreciation and Amortization 1.99 1.99
12% 12%
6%
EBIT (Operating Income) EBIT -124 -124
6% 6%
-361%
Net Profit -112 -112
3% 3%
-326%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Pr...
Neutral
GlobeNewsWire
23 days ago
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab
Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell ...
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 110
Founded 2015
Website c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today